Fekete Gyula Laszlo, Iantovics Laszlo Barna, Fekete Júlia Edit, Fekete Laszlo
Department of Dermatology, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures, 540142 Targu Mures, Romania.
Department of Electrical Engineering and Information Technology, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures, 540142 Targu Mures, Romania.
Life (Basel). 2024 Aug 25;14(9):1062. doi: 10.3390/life14091062.
Durvalumab is an IgG1 monoclonal antibody that has efficacy in many advanced-stage cancers, especially in small-cell lung cancer. The efficacy of durvalumab can be enhanced by chemotherapy. Cutaneous side effects due to treatment with durvalumab are usually self-limiting and easily manageable. We present a clinical case of a female patient aged 61, with small-cell lung carcinoma in stage III B, cT3N2M, who developed a disseminated cutaneous vasculitis after seven months of durvalumab monotherapy, having previously been treated with polychemotherapy according to oncological protocols. To the best of our knowledge, based on a comprehensive search in leading databases, like Web of Science, Scopus, PubMed and some others, ours is the first published case of disseminated cutaneous vasculitis as a result of Durvalumab treatment. Anticancer immunotherapy targeting immune checkpoint inhibition (ICI) has transformed the treatment and evolution of patients with multiple varieties of hematologic cancers. In this context, the cutaneous side effects due to immune checkpoint inhibitor therapies are very few in the scientific literature. Based on this need, we have performed a mini-review of cutaneous side effects due to immune checkpoint inhibitor therapies that treat actual aspects in this sense. We also present some artificial intelligence challenges and future perspectives in the combination of human reasoning and reasoning based on Artificial Intelligence for study of the very rare Disseminate cutaneous vasculitis associated with Durvalumab treatment.
度伐利尤单抗是一种IgG1单克隆抗体，对多种晚期癌症有效，尤其是小细胞肺癌。化疗可增强度伐利尤单抗的疗效。度伐利尤单抗治疗引起的皮肤副作用通常具有自限性且易于处理。我们报告一例61岁女性患者的临床病例，该患者患有III B期小细胞肺癌，cT3N2M，在接受度伐利尤单抗单药治疗七个月后出现播散性皮肤血管炎，此前已根据肿瘤学方案接受多药化疗。据我们所知，通过在Web of Science、Scopus、PubMed等主要数据库中进行全面检索，我们的病例是首例因度伐利尤单抗治疗导致播散性皮肤血管炎的报道。针对免疫检查点抑制（ICI）的抗癌免疫疗法改变了多种血液系统癌症患者的治疗和病程。在此背景下，科学文献中关于免疫检查点抑制剂疗法引起的皮肤副作用描述很少。基于这一需求，我们对免疫检查点抑制剂疗法引起的皮肤副作用进行了简要综述，探讨了这方面的实际情况。我们还提出了一些人工智能挑战以及将人类推理与基于人工智能的推理相结合用于研究与度伐利尤单抗治疗相关的非常罕见的播散性皮肤血管炎的未来展望。
